SLC16A1 has a significantly increased expression level in brain and CNS cancer, esophageal cancer, head and neck cancer, kidney cancer, lung cancer, melanoma, and even sarcoma, indicating its importance in pan-cancer. Here, SLC16A1 is linked to sarcoma.